Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Maintenance Treatment With Capecitabine Plus Apatinib vs. Apatinib and Observation After First-line XELOX/SOX Chemotherapy for Patients With Advanced Gastric Cancer: a Multicenter, Randomized, Controlled Trial

NCT03598348 is registered in ClinicalTrials.gov with Huazhong University of Science and Technology as lead sponsor.

NCT NCT03598348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03598348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Maintenance Treatment With Capecitabine Plus Apatinib vs. Apatinib and Observation After First-line XELOX/SOX Chemotherapy for Patients With Advanced Gastric Cancer: a Multicenter, Randomized, Controlled Trial
Lead sponsor
Huazhong University of Science and Technology
Phase
Phase 3
Overall status
Unknown status
Start date
January 16, 2018
Completion date
October 16, 2020
Enrollment
288 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer